Xeris Biopharma Holdings (XERS) EBIAT: 2020-2025
Historic EBIAT for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $621,000.
- Xeris Biopharma Holdings' EBIAT rose 103.95% to $621,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 75.22%. This contributed to the annual value of -$54.8 million for FY2024, which is 11.92% up from last year.
- According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBIAT is $621,000, which was up 132.21% from -$1.9 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBIAT ranged from a high of $621,000 in Q3 2025 and a low of -$50.8 million during Q4 2021.
- Its 3-year average for EBIAT is -$11.6 million, with a median of -$13.4 million in 2023.
- In the last 5 years, Xeris Biopharma Holdings' EBIAT tumbled by 132.37% in 2021 and then spiked by 103.95% in 2025.
- Quarterly analysis of 5 years shows Xeris Biopharma Holdings' EBIAT stood at -$50.8 million in 2021, then skyrocketed by 74.54% to -$12.9 million in 2022, then declined by 3.56% to -$13.4 million in 2023, then spiked by 61.81% to -$5.1 million in 2024, then skyrocketed by 103.95% to $621,000 in 2025.
- Its last three reported values are $621,000 in Q3 2025, -$1.9 million for Q2 2025, and -$9.2 million during Q1 2025.